BioStock: Green light for Alligator Bioscience and Aptevo Therapeutics

Report this content

Swedish Alligator Bioscience has developed the bispecific antibody ALG.APV-527 together with American biotech Aptevo Therapeutics. Recently, US authorities have given the project a green light to proceed into the clinical phase. The companies will now initiate a phase I trial with the candidate in solid tumours. BioStock reached out to Alligator’s CEO Søren Bregenholt for a comment.

Read the interview with Alligator Bioscience's CEO Søren Bregenholt at biostock.se:

https://www.biostock.se/2022/09/green-light-for-alligator-bioscience-and-aptevo-therapeutics/

This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se/en/

Subscribe

Quick facts

BioStock: Green light for Alligator Bioscience and Aptevo Therapeutics
Tweet this